Dendreon’s Seal Beach plant: advertising campaign aimed at boosting demand for company’s flagship product A top executive of Seattle-based biotech Dendreon Corp., which has a manufacturing plant in ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

Medicare said this week it will pay for two cancer treatments with hefty price tags -- and lingering questions: Avastin, the controversial drug shot down by an Food and Drug Administration panel on ...

Shares of Dendreon Corp. gained Monday, bucking the broader market, as a Lazard Capital analyst upgraded shares on the sales potential for the prostate cancer drug Provenge. The stock rose $1.35, or 7 ...

NEW YORK, Oct 7 (Reuters) - Interest in Dendreon Corp's <DNDN.O> Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's <JNJ.N> more-convenient ...

Dendreon Corp. said Wednesday the Food and Drug Administration agreed to an accelerated timeline for its late-stage clinical trial of Provenge, the biotechnology company's prostate cancer treatment ...

NEW YORK (AP) - The Food and Drug Administration says it has approved a drug that is designed to stimulate a patient's immune system to fight prostate cancer. The agency says it cleared marketing of ...

SAN FRANCISCO, Jan 11 (Reuters) - Dendreon Corp expects to reach full manufacturing capacity for experimental prostate cancer drug Provenge by mid-2011, and will immediately launch sales of the drug ...

BioVest’s immunotherapy BiovaxID®, if approved for follicular lymphoma, will likely gain acceptance on the market more quickly than the Dendreon’s prostate cancer vaccine Provenge, which was the first ...

It’s been more than a decade since Dendreon’s prostate cancer immunotherapy, Provenge, won FDA approval. Now, after a lackluster launch, a bankruptcy and multiple ownership changes, the biopharma is ...